The present invention relates generally to the field of masks used for respiratory therapy. In especially preferred embodiments, the present invention relates to respiratory masks having a gusseted cushion.
Facial masks are well known for use in continuous positive airway pressure (CPAP) treatment of various respiratory ailments and sleep disordered breathing (SDB), such as, for example, obstructive sleep apnea (OSA) and/or other ventilatory assistance treatments such as noninvasive positive pressure ventilation (NPPV). See, for example, U.S. Pat. No. 4,944,210, the entire content of which is expressly incorporated hereinto by reference. While the present invention will be described below with reference to a full facial mask for use in CPAP treatment, it will be understood that such a reference is non-limiting and is directed toward a particularly preferred embodiment of the present invention. Thus, the various characteristics and advantages of the present invention could equivalently be embodied in another type of mask, such as a nasal mask, or another type of NPPV therapy.
Apparatus for the treatment of SDB generally involves a blower which delivers a supply of air at positive pressure to a patient interface via a conduit. The patient interface may take several forms, such as a nasal mask assembly and a nasal and mouth mask assembly (i.e., a full face mask). Patients typically wear a mask assembly while sleeping to receive the NPPV therapy.
Mask assemblies typically include a rigid shell or frame and a soft face-contacting cushion. The cushion cushions the rigid frame from the patient's face, and provides a seal with the patient's face. The frame and cushion define a cavity which receives the nose or nose and mouth. The frame and cushion are held in position on the patient's face by a headgear assembly. The headgear assembly typically comprises an arrangement of straps which pass along both sides of the patient's face to the back or crown of the patient's head.
One problem that arises with existing masks used for CPAP treatments is that over-tightening of the mask straps results in compression of the mask against the wearer's face which may therefore apply undue pressure force against certain of the wearer's facial features, such as the wearer's nose. A poorly fitting mask can leak when pressurized which encourages a patient to tighten the headgear straps excessively which, in turn leads to discomfort, marks on the face and in some cases facial sores.
The cushion of a patient mask interface can play a key role in the comfort and effectiveness of therapy. The nasal bridge area of the patient's face has been identified as being particularly sensitive and thus a mask design needs to pay particular attention to such region.
The issue of mask comfort and effectiveness is particularly apparent when treatment pressure varies, for example, when a patient uses an automatic positive airway pressure (APAP) device such as those commercially available from ResMed Limited under the tradename AUTOSET. When the pressure varies, patients may set the headgear tension for the highest pressure, which thereby leads to unnecessarily high tension being experienced at lower pressures.
To address such problems, mask systems that vary the sealing force with treatment pressure have been developed, including a nasal mask cushion having a gusset portion, as evidenced by U.S. Published Patent Application 2002/0029780; U.S. Pat. No. 6,772,760 and U.S. Published Patent Application US 2004/0118406, the entire content of each being expressly incorporated hereinto by reference. A commercial embodiment of the inventions described in such patent publications is the ACTIVA™ mask system available from ResMed Limited.
U.S. Pat. No. 5,074,297 (the entire content of which is expressly incorporated hereinto by reference) describes a respiratory mask assembly for use with intermittent positive pressure breathing treatment and is said to facilitate the formation and automatic adjustment of the seal between a patient's face and a facial unit of the respiratory mask.
While the prior proposals for adjustable mask cushions may be satisfactory for their intended purposes, improvements are still needed, especially for a full face mask patient interface.
Broadly, one embodiment of the present invention is directed to full face masks for use in respiratory therapy wherein a gusset portion is interposed between the mask cushion and the mask frame. The gusset portion thereby allows for relative movement of the mask frame to occur towards and away from a patient's face to ensure the integrity of sealing contact between the cushion and the patient's facial features and to maintain a desired comfort level.
The gusset portion in accordance with the present invention provides several benefits. For example, the gusset portion utilizes the pressure in the mask acting on its increased surface area to provide a force to maintain the face-contacting portion of the cushion in sealing contact with the patient's face. Of course, the gusset may include a predetermined spring constant that can also affect the force applied to seal against the user's skin. Additionally, the gusset portion provides in effect a decoupling joint between the face-contacting portion of the cushion and the mask shell thereby allowing some relative movement to occur between the mask and the cushion contacting the patient's face. This arrangement substantially protects the seal from undue disturbance when the mask or mask shell is tilted; the facial muscles are relaxed, patient movement occurs, and/or movement of the gas supply tube occurs. This decoupling joint provided by the gusset also allows additional travel between the mask shell and the lower cushion which reduces the precision by which the strap length must be maintained.
The gusset portion of the present invention is especially beneficial in the context of a full face mask since it has at least one perimetrical section which includes generally laterally projecting exterior and interior gusset sections. Both laterally extending exterior and interior gusset sections provide flexibility and increase the allowable travel of the mask frame from the cushion. The laterally projecting exterior section also provides additional sealing pressure to the cushion depending on treatment pressure. Most preferably, the incorporation of the laterally exterior projecting gusset section increases the projected surface area on the patient's face by at least about 260% compared to the projected surface area of the face-contacting portion of the cushion alone. For example, in an embodiment, the projected surface area of the face-contacting portion alone is about 50 cm2 and the projected surface area of the gusset section alone is in the range of 30-90 cm2, preferably about 80 cm2. Thus, the gusset section adds about 80 cm2 extra area to the cushion or about 160% (80/50) extra area compared to the cushion alone. As a result, the total projected surface area of the gusseted cushion is equal to the summation of the face-contacting portion and the gusset section which is in the range of 80-140 cm2, preferably about 130 cm2 (80+50), and this total area is about 260% (130/50) of the projected surface area of the face-contacting portion alone.
One aspect of the gusseted cushion according to the present invention is the greater projected area that may be achieved in a particular facial region of the patient which leads to additional sealing force per unit mask pressure that may be obtained at such region. By varying the widthwise extent that the gusset projects laterally outwardly around the perimeter of the mask, the amount of pressure-dependent additional sealing force can be varied since pressure acts upon the additional area from the sealing point of the cushion on the face to the exterior of the gusset and provides a force on the cushion. For example, according to an aspect of the present invention, the sealing force may be reduced in sensitive facial areas of the patient, such as the region of the patient's nasal bridge by reducing the widthwise extent of the gusset in this region.
The amount of additional area that the laterally outwardly extending gusset is required to project is also dependent upon the treatment pressure. A relatively large area Ag (e.g. 300 cm2 when compared to the projected area of the cushion Ac of 50 cm2, see
Another aspect of the gusset is the travel available in a particular patient facial region. Travel allows movement to occur between the frame contacting portion and the patient contacting portion of the cushion between which the gusset is disposed. In general, a cushion in accordance with the invention allows substantially the same amount of travel around the entirety of the cushion's perimeter so that the frame and patient contacting portions can remain generally parallel. This is achieved by varying the width of the interior projecting gusset or gussets to maintain the amount of travel regardless of the width of the exterior projecting gusset which is tailored to meet the particular sealing force requirements of the facial region. In use there may in fact be non-parallel travel movement of the frame relative to the patient's face due to the inherent flexibility of their material of construction. In this regard, the gusseted cushions of the present invention most preferably provide between about 5 mm to about 25 mm, advantageously about 16 mm (+/−1 mm), of travel distance when embodied in a full face mask.
The present invention may be embodied in a cushion for a respiratory mask assembly having a frame-connecting portion, a face-contacting portion, and a gusset portion disposed between and joining the frame-connecting and face-contacting portions. The gusset portion preferably includes at least one perimetrical region which has a laterally projecting exterior gusset section and a laterally projecting interior gusset section.
According to one aspect, the laterally projecting exterior and interior gusset sections are disposed about the entire perimeter to the gusset portion so as to establish a substantially constant widthwise dimension thereof about the gusset's entire perimeter. According to another aspect, the laterally projecting exterior and interior gusset sections of the gusset project only along a lower perimetrical region thereof so that the gusset portion has a widthwise dimension which varies about its perimeter.
In another aspect, the gusset portion has a minimum widthwise dimension at an upper perimetrical region thereof, a maximum widthwise dimension at a lower perimetrical region thereof, and widthwise transitions joining said upper and lower perimetrical regions thereof. The widthwise transitions may be either curvilinear or linear.
Another aspect of the present invention is a cushion for a respiratory mask having a frame-connecting portion, a face-contacting portion, and a gusset portion disposed between and joining the frame-connecting and face-contacting portions, wherein said gusset portion has a perimeter with a widthwise dimension which varies between at least one region and another perimetrical region thereof. In a preferred aspect, the gusset portion has a minimum widthwise dimension at an upper perimetrical region thereof, a maximum widthwise dimension at a lower perimetrical region thereof, and widthwise transitions (which may be curvilinear or linear) joining such upper and lower perimetrical regions thereof.
In one specific aspect, the cushion of the present invention substantially zero widthwise dimension at said upper perimetrical region thereof. In accordance with another aspect of the invention, each of the minimum and maximum widthwise dimensions is substantially constant along the upper and lower perimetrical regions, respectively.
According to another aspect, the invention has an upper perimeter region which occupies between about 15% to about 30% of the entire perimeter of the cushion, a lower perimeter region which occupies between about 50% to about 70% of the entire perimeter of the cushion, and transition regions which occupy between about 10% to about 30% of the entire perimeter of the cushion.
These and other aspects and advantages will become more apparent after careful consideration is given to the following detailed description of the preferred exemplary embodiments thereof.
Reference will hereinafter be made to the accompanying drawings, wherein like reference numerals throughout the various FIGURES denote like structural elements, and wherein:
An exemplary embodiment of a full facial mask assembly FMA which includes a cushion 10 also referred to as a gusseted cushion) according to one embodiment of the present invention is depicted in accompanying
Strap connectors 26 extend laterally from the mask frame 20 so as to allow attachment of straps associated with a conventional headgear assembly (not shown) and thereby permit the mask assembly FMA to be secured to a wearer's head when in use. The mask frame 20 may also be provided with a receiver 28 which is adapted to receive a slide bar associated with a forehead support assembly (not shown), for example, a forehead support assembly of the variety disclosed in commonly owned U.S. Provisional Patent Application Ser. No. 60/735,823, filed Nov. 14, 2005, the entire content of which is expressly incorporated hereinto by reference. A number of vents 30 may be provided so as to allow gas exhaled by the patient to vent to atmosphere. In addition, an auxiliary port 32 may be provided so as to allow the introduction of an auxiliary breathable gas to the mask interior as may be desired, or the port 32 may allow for the measure of pressure within the interior of the mask.
Accompanying
In the embodiment depicted in
It is to be understood that the projected surface areas and associated percentage calculations described herein are merely exemplary and other sizes and percentages are possible depending on application. For example, the sizes and percentages described above may be for a medium sized gusseted cushion, and the sizes and associated percentage calculations may be applied proportionally to other sized cushions, e.g., extra small, small, and large.
It will be observed that the gusset portion 16 according to the embodiment depicted in
Accompanying
It will be observed in
Alternatively or additionally, the extremities of the sections 40 and 42 where each joins the mask-connecting portion 12 and the face-contacting portion 14, respectively, may be thickened as shown in
A full facial mask assembly FMA employing another embodiment of a cushion 10A also referred to as a gusseted cushion) in accordance with the present invention is depicted in
As can be seen in
The non-uniform width regions W1 and W2 thus have the benefits of providing less visual obstruction near the eye region of the patient and less force applied at the patient's nasal bridge region due to the presence of the minimal width region W1 thereat. In addition, the center of the applied force against the patient's face is positioned lower as compared to the cushion 10 with a substantially constant width gusset as discussed previously due to the greater projected width area being located physically lower in the cushion 10A.
Thus, as depicted in
Accompanying
In
Another embodiment of a cushion 10B also referred to as a gusseted cushion) in accordance with the present invention is depicted in
As is shown in
The projected area of the gusset 16B, Ag, is preferably between about 80 cm2 to about 140 cm2, more preferably approximately 130 cm2, as measured in its natural molded state (i.e., uncompressed). Of course, the area could be higher or lower, depending on application. In this regard, since little additional sealing force is required in the nasal bridge region, the upper gusset region 16B-1 does not necessarily require any projected area, hence the zero or near zero width in that region. Moreover, the substantially straight side regions impart structural stability to the gusset 16B in the upper region 16B-1. Also, the gusset 16B in the nasal bridge region has a generally w-shaped cross-sectional configuration (see
It will be observed in the cross-sections of
While the invention has been described in connection with what are presently considered to be the most practical and preferred embodiments, it is to be understood that the invention is not to be limited to the disclosed embodiments, but on the contrary, is intended to cover various modifications and equivalent arrangements included within the spirit and scope of the invention. Also, the various embodiments described above may be implemented in conjunction with other embodiments, e.g., aspects of one embodiment may be combined with aspects of another embodiment to realize yet other embodiments. In addition, while the invention has particular application to patients who suffer from OSA, it is to be appreciated that patients who suffer from other illnesses (e.g., congestive heart failure, diabetes, morbid obesity, stroke, barriatric surgery, etc.) can derive benefit from the above teachings. Moreover, the above teachings have applicability with patients and non-patients alike in non-medical applications.
This application is a continuation of U.S. patent application Ser. No. 15/063,825, filed Mar. 8, 2016, which is a continuation of U.S. patent application No. U.S. Ser. No. 13/654,600, filed Oct. 18, 2012, now U.S. Pat. No. 9,308,342, which is continuation of U.S. patent application Ser. No. 11/793,051, filed Dec. 8, 2008, now U.S. Pat. No. 8,297,283, which is the U.S. National Phase of International Application No. PCT/AU2006/000034, filed Jan. 12, 2006, which designated the U.S. and claims the benefit of U.S. Provisional Application No. 60/643,115, filed Jan. 12, 2005, the entirety of each of which is incorporated herein by reference. Also, PCT Application No. PCT/AU2005/000850, filed Jun. 15, 2005, is expressly incorporated hereinto by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
2130555 | Malcom | Sep 1938 | A |
2133699 | Heidbrink | Oct 1938 | A |
2371965 | Lehmberg | Mar 1945 | A |
2428451 | Emerson | Oct 1947 | A |
2444417 | Bierman | Jul 1948 | A |
2625155 | Engelder | Jan 1953 | A |
2706983 | Matheson et al. | Apr 1955 | A |
2882895 | Galeazzi | Apr 1959 | A |
2931356 | Schwarz | Apr 1960 | A |
3796216 | Schwarz | Mar 1974 | A |
4062357 | Laerdal | Dec 1977 | A |
4069516 | Watkins, Jr. | Jan 1978 | A |
4265239 | Fischer, Jr. et al. | May 1981 | A |
4328797 | Rollins et al. | May 1982 | A |
4739755 | White et al. | Apr 1988 | A |
4770169 | Schmoegner et al. | Sep 1988 | A |
4907584 | McGinnis | Mar 1990 | A |
4944210 | Flock et al. | Jul 1990 | A |
4928835 | Collette et al. | Sep 1990 | A |
4971051 | Toffolon | Nov 1990 | A |
5062421 | Burns et al. | Nov 1991 | A |
5074297 | Venegas | Dec 1991 | A |
5243971 | Sullivan et al. | Sep 1993 | A |
5349949 | Shegerin | Sep 1994 | A |
5353789 | Schlobohm | Oct 1994 | A |
5355878 | Griffiths et al. | Oct 1994 | A |
5391248 | Brain | Feb 1995 | A |
5429683 | Le Mitouard | Jul 1995 | A |
5438981 | Starr et al. | Aug 1995 | A |
5540223 | Starr et al. | Jul 1996 | A |
5579761 | Yuschak et al. | Dec 1996 | A |
5647357 | Barnett et al. | Jul 1997 | A |
5649532 | Griffiths | Jul 1997 | A |
5662101 | Ogden et al. | Sep 1997 | A |
5724965 | Handke et al. | Mar 1998 | A |
5918598 | Belfer et al. | Jul 1999 | A |
5921239 | McCall et al. | Jul 1999 | A |
5935136 | Hulse et al. | Aug 1999 | A |
5975079 | Hellings et al. | Nov 1999 | A |
6016804 | Gleason et al. | Jan 2000 | A |
6112746 | Kwok | Sep 2000 | A |
6192886 | Rudolph | Feb 2001 | B1 |
6412487 | Gunaratnam et al. | Jul 2002 | B1 |
6412488 | Barnett et al. | Jul 2002 | B1 |
6467483 | Kopacko et al. | Oct 2002 | B1 |
6467843 | Kopacko et al. | Oct 2002 | B1 |
6513526 | Kwok et al. | Feb 2003 | B2 |
6626177 | Ziaee | Sep 2003 | B1 |
6772760 | Frater et al. | Aug 2004 | B2 |
6851425 | Jaffree et al. | Feb 2005 | B2 |
6851428 | Dennis | Feb 2005 | B2 |
7523754 | Lithgow et al. | Apr 2009 | B2 |
7827990 | Melidis et al. | Nov 2010 | B1 |
7900630 | Geiselhart et al. | Mar 2011 | B2 |
7971590 | Frater et al. | Jul 2011 | B2 |
8297283 | Hitchcock et al. | Oct 2012 | B2 |
8522784 | Ng et al. | Sep 2013 | B2 |
8528561 | Ng et al. | Sep 2013 | B2 |
8550084 | Ng et al. | Oct 2013 | B2 |
8820327 | Melidis et al. | Sep 2014 | B2 |
9308342 | Hitchcock et al. | Apr 2016 | B2 |
9375545 | Darkin | Jun 2016 | B2 |
9522246 | Frater | Dec 2016 | B2 |
10449315 | Hitchcock | Oct 2019 | B2 |
20020029780 | Frater | Mar 2002 | A1 |
20020043265 | Barnett et al. | Apr 2002 | A1 |
20030019495 | Palkon et al. | Jan 2003 | A1 |
20030089372 | Frater et al. | May 2003 | A1 |
20040118406 | Lithgow et al. | Jun 2004 | A1 |
20040144386 | Frater et al. | Jul 2004 | A1 |
20060032504 | Burton | Feb 2006 | A1 |
20060042629 | Geist | Mar 2006 | A1 |
20060272646 | Ho et al. | Dec 2006 | A1 |
20070044804 | Matula, Jr. et al. | Mar 2007 | A1 |
20070163600 | Hoffman | Jul 2007 | A1 |
20070267017 | McAuley et al. | Nov 2007 | A1 |
20090095301 | Hitchcock et al. | Apr 2009 | A1 |
20090139526 | Melidis et al. | Jun 2009 | A1 |
20100282265 | Melidis et al. | Nov 2010 | A1 |
20130037033 | Hitchcock et al. | Feb 2013 | A1 |
20130133660 | Ng et al. | May 2013 | A1 |
20130327333 | Ng et al. | Dec 2013 | A1 |
20140338672 | D'Souza et al. | Nov 2014 | A1 |
20160206843 | Hitchcock et al. | Jul 2016 | A1 |
Number | Date | Country |
---|---|---|
4 233 448 | Apr 1993 | DE |
196 03 949 | Aug 1997 | DE |
0 334 555 | Sep 1989 | EP |
0 303 090 | Apr 1992 | EP |
0 747 078 | Dec 1996 | EP |
0 853 962 | Jul 1998 | EP |
1 057 494 | Dec 2000 | EP |
649689 | Jan 1951 | GB |
11-000397 | Jan 1999 | JP |
2003-535657 | Dec 2003 | JP |
232296 | Jan 1990 | NZ |
556043 | Jan 2011 | NZ |
WO 9700092 | Jan 1997 | WO |
WO 9804310 | Feb 1998 | WO |
WO 9834665 | Aug 1998 | WO |
9921618 | May 1999 | WO |
WO 0162326 | Aug 2001 | WO |
WO 0197893 | Dec 2001 | WO |
WO 2004022146 | Mar 2004 | WO |
WO 2004071565 | Aug 2004 | WO |
2005118042 | Dec 2005 | WO |
WO 2005123166 | Dec 2005 | WO |
WO 2006074515 | Jul 2006 | WO |
WO 2006138416 | Dec 2006 | WO |
WO 2007147088 | Dec 2007 | WO |
WO 2009108995 | Sep 2009 | WO |
Entry |
---|
International Search Report for PCT/AU2006/000034, dated Mar. 6, 2006. |
U.S. Appl. No. 60/735,823, filed Nov. 14, 2005, first named inventor: Vincent Chu. |
International Preliminary Report on Patentability, PCT/AU2006/000034 (dated Jul. 17, 2007). |
European Sear Report issued in EP 06 70 4770 (dated Oct. 20, 2009). |
Examiner's First Report issued in related Australian Appl. No. 2006206042 (dated Feb. 14, 2011). |
Office Action issued in related European Appl. No. 06704770.4 (dated Mar. 28, 2011). |
Office Action issued in related Japanese Appl. No. 2007-550638 (dated May 10, 2011). |
Office Action issued in related New Zealand Appl. No. 589953 (dated Dec. 22, 2010). |
Office Action issued in related Chinese Appl. No. 201010151817.0 (dated Aug. 22, 2011) with English translation. |
Examination Report issued in related New Zealand Appl. No. 598811 (dated Mar. 26, 2012). |
Notice of Allowance issued in related Japanese Appl. No. 2007-550638 (dated May 8, 2012). |
Communication issued in a corresponding European Application No. 06 704 770.4 dated Jun. 18, 2013. |
First Examination Report issued in a corresponding New Zealand Application No. 614344 dated Aug. 21, 2013. |
Summons to Attend Oral Proceedings issued in a corresponding European Appln. No. 06 704 770.4 dated Jun. 5, 2014. |
Decision to Refuse a European Patent Application issued in corresponding Patent Appln. No. 06 704 770.4, dated Oct. 23, 2014. |
Amended Notice of Opposition to Grant of Patent filed by Fisher & Paykel Healthcare Limited in New Zealand Patent Application No. 622665 and Statement of Case filed on Oct. 30, 2014 (27 pages). |
Amended Notice of Opposition to Grant of Patent filed by Fisher & Paykel Healthcare Limited in New Zealand Patent Application No. 622670 and Statement of Case filed on Oct. 30, 2014 (27 pages). |
Amended Notice of Opposition to Grant of Patent filed by Fisher & Paykel Healthcare Limited in New Zealand Patent Application No. 607032 and Statement of Case filed on Oct. 30, 2014 (27 pages). |
Amended Notice of Opposition to Grant of Patent filed by Fisher & Paykel Healthcare Limited in New Zealand Patent Application No. 622666 and Statement of Case filed on Oct. 30, 2014 (26 pages). |
First Examination Report issued in corresponding New Zealand Application No. 703971 dated Feb. 2, 2015. |
First Examination Report issued in corresponding New Zealand Application No. 722620 dated Aug. 18, 2016. |
Notice of Opposition filed Dec. 23, 2016 by Fisher & Paykel Healthcare Limited in New Zealand Application No. 703971 (2 pages). |
Deadline for Counterstatement dated Mar. 28, 2017 issued in New Zealand Application No. 703971 (2 pages). |
Filing Cover Sheet dated Mar. 27, 2017 from AJ Park in New Zealand Application No. 703971 (1 page). |
Amended Notice of Opposition to Grant of Patent dated Mar. 27, 2017 filed by Fisher & Paykel Healthcare Limited in New Zealand Application No. 703971 with Mark-ups (2 pages). |
Amended Notice of Opposition to Grant of Patent dated Mar. 27, 2017 filed by Fisher & Paykel Healthcare Limited in New Zealand Application No. 703971 without Mark-ups (2 pages). |
Statement of Case dated Mar. 27, 2017 filed by Fisher & Paykel Healthcare Limited in New Zealand Application No. 703971 (14 pages). |
Communication regarding Proceeding Halt dated Jul. 3, 2017 issued in New Zealand Application No. 703971, Proceeding No. 3340 (1 page). |
Correspondence Requesting Opposition is Put on Hold dated Jun. 22, 2017 filed in New Zealand Application No. 703971, Proceeding No. 3340 by Fisher & Paykel Healthcare Limited (7 pages). |
Further Examination Report dated Dec. 11, 2017 issued in New Zealand Application No. 722620 (1 page). |
First Examination Report dated Feb. 16, 2018 issued in New Zealand Application No. 739403 (3 pages). |
Opponent's Bundle of Authorities filed May 28, 2018 by Fisher & Paykel Heathcare Limited in New Zealand Application Nos. 599406 and 703971 (286 pages). |
Opponent's Submissions on Adequacy of Counterstatements filed May 28, 2018 by Fisher & Paykel Heathcare Limited in New Zealand Application Nos. 599406 and 703971 (18 pages). |
Amended Statement of Case dated Aug. 13, 2018 filed by Fisher & Paykel Healthcare Limited in New Zealand Application No. 703971 (17 pages). |
Second Amended Notice of Opposition to Grant of Patent dated Aug. 13, 2018 filed by Fisher & Paykel Healthcare Limited in New Zealand Application No. 703971 (2 pages). |
EP Communication dated Apr. 30, 2020 in European Application No. 06704770.4 (Appeal No. T0547/15-3.2.02) forwarding Decision on Appeal dated Apr. 22, 2020, 13 pages. |
Number | Date | Country | |
---|---|---|---|
20190388637 A1 | Dec 2019 | US |
Number | Date | Country | |
---|---|---|---|
60643115 | Jan 2005 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15063825 | Mar 2016 | US |
Child | 16561307 | US | |
Parent | 13654600 | Oct 2012 | US |
Child | 15063825 | US | |
Parent | 11793051 | US | |
Child | 13654600 | US |